Mammograms at Richard D. Adelman M.D. in Raleigh, North Carolina: FDA Safety Communication - Quality Problems
The facility may not perform mammography due to the revocation of its accreditation.
Italiano
The facility may not perform mammography due to the revocation of its accreditation.
Postmarketing cases of serious and life-threatening symptomatic bradycardia, as well as one fatal cardiac arrest and cases requiring pacemaker insertion, have been reported.
FDA is unable to exclude the possibility that the deaths were caused by rapid, but delayed, entry of the drug into the bloodstream following intramuscular injection.
If asthma is not appropriately treated and managed, patients may be at risk for life-threatening asthma attacks.
L'Agenzia Italiana del Farmaco rende disponibili aggiornamenti sulla concentrazione di radioattività contenuta nelle fiale di Xofigo® (radio-223 dicloruro).
A multi-factorial etiology
Non-steroidal anti-inflammatory drugs (NSAIDs) are used in paediatrics as antipyretics, anti-inflammatories and analgesics. They are products with high bioavailability, are metabolized in the liver and some (naproxen, ibuprofen, ketoprofen) partially in the kidneys as well.
For over 50 years, benzodiazepines have been a veritable "best seller". The key to their continued success is due not only to their easy management and widespread prescription, but also to their potential to induce dependence and tolerance, which is why their use is only recommended for a very limited time. These recommendations, however, have been largely disregarded by medical practitioners, the government regulatory bodies and, last but not least, by patients themselves.
"Can we rely on RE-LY?" was the title of an editorial in the New England Journal of Medicine1 in 2009, commenting on the RE-LY study2 which compared dabigatran (110 and 150 mg), the first member of the new class of oral anticoagulants, and warfarin in patients with non-valvular atrial fibrillation at risk of stroke.
Il Comitato di Valutazione del Rischio per la Farmacovigilanza
(Pharmacovigilance Risk Assessment Committee, PRAC) dell’Agenzia Europea
del Farmaco (European Medicine Agency, EMA) ha completato la revisione
periodica di uno dei medicinali a base di bifosfonati con un rischio
noto di osteonecrosi della mandibola/mascella.
80.211.154.110